Trump in tweet denies chaos at White House
President Donald Trump is insisting there is no chaos in his White House.
Now we’re parking — automatically
Most of the hype for automated driving deals with driving down the road with the eyes diverted from the road, hands off the steering wheel, and the driver relinquishing control.
read more
...Read the rest of this story
Phillips restructures sales team
AP Exclusive: Parole for young lifers inconsistent across US
DETROIT (AP) — Courtroom 801 is nearly empty when guards bring in Bobby Hines, hands cuffed in front of navy prison scrubs.
Fleetmatics: Using GPS and tracking to help prevent vehicle theft
read more
...Read the rest of this story
AstraZeneca rally continues as US regulator endorses cancer drug
AstraZeneca's share price rally continued this morning on news that its leading immuno-oncology drug Imfinzi has been granted ‘breakthrough' status by US regulators, despite a major setback in its long-awaited ‘Mystic' clinical trial last week that wiped £10bn from its market value. The Food and Drug Administration (FDA) decision means that Imfinzi will be reviewed more quickly for treatments relating to previously treated non-metastatic lung cancer. This means it could potentially be launched more quickly. An AstraZeneca trial called Pacific, which reported in May, found patients with this kind of cancer were responsive to Imfinzi. The cause of the company's share price crash last Thursday stemmed from a negative result from Mystic, a separate trial of Imfinzi that targeted the larger, advanced lung cancer market. AstraZeneca share price AstraZeneca shares dived 16pc on the Mystic results to below £43, down from the previous day's close of £51, their biggest single day fall. But they rallied slightly on Friday and continued to claw back some of their losses today on the FDA news, edging up more than 2pc in early afternoon trading to just shy of the £46 mark. However, in more negative news, ratings agency Moody's followed Standard & Poor's lead from last Friday and downgraded AstraZeneca's borrowing a notch to A3- as a result of the Mystic readout. Standard & Poor's had reduced its rating to BBB+. Sean Bohen, chief medical officer at AstraZeneca, said: "For patients who have not progressed following chemoradiation therapy the only current option is active monitoring. “Unfortunately, for the majority of patients, their cancer will progress to metastatic disease, typically within 12 months. Timeline | Cancer breakthoughs “Imfinzi is the first immuno-oncology medicine to show a clinically significant benefit in this earlier, non-metastatic setting, so following the Breakthrough designation we hope to bring it ...Read the rest of this story
SRTs vs. hourly shop rate
Shops bill for their labor hours using either Standard Repair Times, by establishing their own estimated repair times, or actual technician repair time.
Truck makers, component suppliers and even third party publishers offer SRT guides to help establish acceptable times for specific repairs. Standard repair times for a specific repair can vary based on what method the source used to develop the standard. In addition, manufactures typically have a separate SRT established for their dealer warranty time reimbursement.
read more
...Read the rest of this story